Difference between revisions of "Gemcitabine (Gemzar)"
m |
|||
| Line 36: | Line 36: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Irritant chemotherapy]] | ||
| + | [[Category:Pyrimidine analogues]] | ||
| + | |||
| + | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
| + | [[Category:Bladder cancer medications]] | ||
| + | [[Category:Bone cancer medications]] | ||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Cancer of unknown primary medications]] | ||
| + | [[Category:Cervical cancer medications]] | ||
| + | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Head and neck cancer medications]] | ||
| + | [[Category:Hepatobiliary cancer medications]] | ||
| + | [[Category:Hodgkin lymphoma medications]] | ||
| + | [[Category:Mesothelioma medications]] | ||
| + | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Ovarian cancer medications]] | ||
| + | [[Category:Pancreatic cancer medications]] | ||
| + | [[Category:Renal cancer medications]] | ||
| + | [[Category:Sarcoma medications]] | ||
| + | [[Category:Small cell lung cancer medications]] | ||
| + | [[Category:T-cell lymphoma medications]] | ||
| + | [[Category:Testicular cancer medications]] | ||
Revision as of 16:58, 5 September 2014
General information
Class/mechanism: Pyrimidine analog; metabolized within cells to the active nucleoside forms: diphosphate (dFdCDP) and triphosphate (dFdCTP). Gemcitabine diphosphate inhibits ribonucleotide reductase, which catalyzes reactions that produce deoxynucleoside triphosphates for DNA synthesis. This inhibition of deoxynucleoside triphosphates helps gemcitabine triphosphate to compete with deoxycytidine triphosphate (dCTP) to be incorporated into DNA. DNA synthesis is halted, since only one additional nucleotide can be added to a DNA strand after gemcitabine is incorporated.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Aggressive Non-Hodgkin lymphoma
- Bladder cancer
- Bone cancer
- Breast cancer
- Cervical cancer
- Esophageal cancer
- Head and neck cancer
- Hepatobiliary cancer
- Hodgkin lymphoma
- Mesothelioma
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic cancer
- Renal cancer
- Sarcoma
- Small cell lung cancer
- T-cell lymphoma
- Testicular cancer
- Unknown primary
Patient drug information
- Gemcitabine (Gemzar) patient drug information (Chemocare)[3]
- Gemcitabine (Gemzar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/15/1996: Initial FDA approval
References
- Irritant chemotherapy
- Pyrimidine analogues
- Aggressive Non-Hodgkin lymphoma medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Cancer of unknown primary medications
- Cervical cancer medications
- Esophageal cancer medications
- Head and neck cancer medications
- Hepatobiliary cancer medications
- Hodgkin lymphoma medications
- Mesothelioma medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Renal cancer medications
- Sarcoma medications
- Small cell lung cancer medications
- T-cell lymphoma medications
- Testicular cancer medications